MX2015004576A - Pruebas diagnosticas para la terapia con inhibidor de quinasas de la familia tec. - Google Patents

Pruebas diagnosticas para la terapia con inhibidor de quinasas de la familia tec.

Info

Publication number
MX2015004576A
MX2015004576A MX2015004576A MX2015004576A MX2015004576A MX 2015004576 A MX2015004576 A MX 2015004576A MX 2015004576 A MX2015004576 A MX 2015004576A MX 2015004576 A MX2015004576 A MX 2015004576A MX 2015004576 A MX2015004576 A MX 2015004576A
Authority
MX
Mexico
Prior art keywords
kinase
probe
optionally substituted
antibody
inhibitor
Prior art date
Application number
MX2015004576A
Other languages
English (en)
Spanish (es)
Inventor
Betty Y Chang
Stella Chang
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of MX2015004576A publication Critical patent/MX2015004576A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2015004576A 2012-10-11 2013-10-11 Pruebas diagnosticas para la terapia con inhibidor de quinasas de la familia tec. MX2015004576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712675P 2012-10-11 2012-10-11
PCT/US2013/064688 WO2014059368A1 (en) 2012-10-11 2013-10-11 Companion diagnostics for tec family kinase inhibitor therapy

Publications (1)

Publication Number Publication Date
MX2015004576A true MX2015004576A (es) 2015-07-21

Family

ID=49510539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004576A MX2015004576A (es) 2012-10-11 2013-10-11 Pruebas diagnosticas para la terapia con inhibidor de quinasas de la familia tec.

Country Status (11)

Country Link
US (1) US20150260723A1 (https=)
EP (1) EP2906556A1 (https=)
JP (1) JP2015536446A (https=)
KR (1) KR20150065871A (https=)
CN (1) CN104755474A (https=)
AU (1) AU2013328961A1 (https=)
BR (1) BR112015008042A2 (https=)
CA (1) CA2887697A1 (https=)
HK (1) HK1213892A1 (https=)
MX (1) MX2015004576A (https=)
WO (1) WO2014059368A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
AU2015360547A1 (en) * 2014-12-11 2017-06-01 Merck Patent Gmbh Assays for BTK inhibitors
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
GB201502393D0 (en) * 2015-02-13 2015-04-01 Univ Leicester Senescence
WO2017141881A1 (ja) * 2016-02-15 2017-08-24 ノーベルファーマ株式会社 遺伝性疾患に関わるタンパク質の測定方法及び測定キット
JP2019524700A (ja) * 2016-07-14 2019-09-05 ミングサイト ファーマシューティカルズ，インク． 癌の処置
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
US20190376971A1 (en) * 2017-01-19 2019-12-12 Acerta Pharma B.V. Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
AU2022284369A1 (en) 2021-06-04 2024-01-25 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
CN114200145A (zh) * 2022-02-18 2022-03-18 上海益诺思生物技术股份有限公司 酪氨酸激酶浓度的检测方法及试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途

Also Published As

Publication number Publication date
AU2013328961A1 (en) 2015-05-07
EP2906556A1 (en) 2015-08-19
KR20150065871A (ko) 2015-06-15
US20150260723A1 (en) 2015-09-17
CA2887697A1 (en) 2014-04-17
CN104755474A (zh) 2015-07-01
JP2015536446A (ja) 2015-12-21
HK1213892A1 (zh) 2016-07-15
BR112015008042A2 (pt) 2017-07-04
WO2014059368A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
MX2015004576A (es) Pruebas diagnosticas para la terapia con inhibidor de quinasas de la familia tec.
CA2668286C (en) Bruton's tyrosine kinase activity probe and method of using
KR101425248B1 (ko) 브루톤 티로신 키나제의 억제제
JP6454672B2 (ja) イソキノリノンの調製方法及びイソキノリノンの固体形態
ES2709108T3 (es) Compuestos heterocíclicos y usos de los mismos
JP2018533939A (ja) Ｒａｓの阻害剤をスクリーニングするための方法
KR20120063515A (ko) Ｐｉ３ 키나제 억제제 및 이들의 용도
KR20160043534A (ko) 선택적 ｇｒｐ９４ 저해제 및 이의 용도
Meisner et al. Terminal adenosyl transferase activity of posttranscriptional regulator HuR revealed by confocal on-bead screening
JP2011528560A (ja) 新規キナーゼ阻害剤足場の迅速なスクリーニングおよび同定のための蛍光標識またはスピン標識キナーゼ
Feng et al. Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma
Elshihawy et al. Design, synthesis, and enzyme kinetics of novel benzimidazole and quinoxaline derivatives as methionine synthase inhibitors
Venkatesan et al. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors
US10125387B2 (en) Compounds, substrates and methods related to histone deacetylases
US11105813B2 (en) Method for target protein identification using thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis
ES2412380T3 (es) Procedimiento para la identificación de compuestos novedosos que interaccionan con enzimas
RU2619932C1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
RU2466132C1 (ru) ИНГИБИТОР PIM1-КИНАЗЫ 6-[(4-МЕТИЛ-1-1-ПИПЕРАЗИНИЛ)МЕТИЛ]-ИНДОЛО[1',7':1,2,3]ПИРРОЛО[3',4':6,7]АЗЕПИНО[4,5-b]ИНДОЛ-1,3(2Н, 10Н)-ДИОН, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
WO2016100593A1 (en) Methods and assays for quantification and normalization of kinase and ligand binding
Liu Development of kinase inhibitors and activity-based probes
Gamage Development and Application of Chemical Tools to Identify Kinase-Substrate Interactions
Mazzucato Design and Synthesis of Novel Kinase Inhibitors for the Treatment of Chronic Respiratory Diseases
US20180372746A1 (en) High-throughput screening assay
JP2017537327A (ja) Ｂｔｋ阻害剤のアッセイ
HK1132744B (en) Bruton's tyrosine kinase activity probe and method of using